BMS-813160
- Generic Name
- BMS-813160
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H40N8O2
- CAS Number
- 1286279-29-5
- Unique Ingredient Identifier
- 83U7957287
- Background
BMS-813160 is under investigation in clinical trial NCT03496662 (BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)).
- Associated Conditions
- -
- Associated Therapies
- -
Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)
- Conditions
- Interventions
- First Posted Date
- 2019-10-10
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 48
- Registration Number
- NCT04123379
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
- Conditions
- Interventions
- First Posted Date
- 2018-04-12
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 40
- Registration Number
- NCT03496662
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 332
- Registration Number
- NCT03184870
- Locations
- 🇺🇸
Local Institution - 0004, Hackensack, New Jersey, United States
🇺🇸Local Institution - 0033, Boston, Massachusetts, United States
🇺🇸Local Institution - 0027, Rochester, Minnesota, United States
A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2016-12-19
- Last Posted Date
- 2022-12-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 182
- Registration Number
- NCT02996110
- Locations
- 🇦🇹
Local Institution - 0044, Linz, Oberösterreich, Austria
🇺🇸Local Institution - 0043, Charlotte, North Carolina, United States
🇺🇸Local Institution - 0007, Baltimore, Maryland, United States
Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2012-12-19
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 319
- Registration Number
- NCT01752985
- Locations
- 🇺🇸
Academic Medical Research Institute, Los Angeles, California, United States
🇨🇦Recherche Gcp Research, Montreal, Quebec, Canada
🇨🇦Eastern Health Sciences Center, St. John's, Newfoundland and Labrador, Canada
Single Ascending Dose (BMS-813160) Study
- Conditions
- Interventions
- First Posted Date
- 2010-01-14
- Last Posted Date
- 2011-02-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 70
- Registration Number
- NCT01049165
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc., Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.